Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimta LabsBOM:524394 -2.55%84 PE Ratio (TTM) is 34.90 as of Aug. 16, 2026, which is 35% above its 10-year median of 25.85. GuruFocus rates BOM:524394 with a GF Score™ of 84/100 and a GF Value™ of ₹508.85 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 96 Medical Diagnostics & Research companies, Vimta Labs ranks worse than 55.21% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-16), Vimta Labs's share price is
₹616.30.
Vimta Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹17.66. Therefore, Vimta Labs's PE Ratio (TTM) for today is 34.90.
The historical rank and industry rank for Vimta Labs's PE Ratio (TTM) or its related term are showing as below:
BOM:524394'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 9.77 Med: 25.85 Max: 77.46
Current: 34.9
During the past 13 years, the highest PE Ratio (TTM) of Vimta Labs was 77.46. The lowest was 9.77. And the median was 25.85.
BOM:524394's PE Ratio (TTM) is ranked worse than 55.21% of 96
companies
in the Medical Diagnostics & Research industry
Industry Median: 32.565
vs BOM:524394: 34.90
As of today (2026-08-16), Vimta Labs's share price is ₹616.30.
Vimta Labs's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was ₹17.93. Therefore, Vimta Labs's PE Ratio without NRI for today is 34.37.
During the past 13 years, Vimta Labs's highestPE Ratio without NRI was 77.46. The lowest was 6.76. And the median was 24.09.
Vimta Labs's EPS without NRI for the
three
months ended in Jun. 2026 was ₹4.66.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was ₹17.93.
During the past 12 months, Vimta Labs's average EPS without NRIGrowth Rate was 12.60% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 18.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 22.60% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 25.80% per year.
During the past 13 years, Vimta Labs's highest 3-Year average EPS without NRI Growth Rate was 87.90% per year. The lowest was -12.40% per year. And the median was 16.20% per year.
Vimta Labs's EPS (Basic) for the
three
months ended in Jun. 2026 was ₹4.71.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹17.86.
Vimta Labs (BOM:524394) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Vimta Labs PE Ratio (TTM) Related Terms
Vimta Labs PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Vimta Labs's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524394 vs TMO, DHR, IDXX: PE Ratio (TTM) Comparison
For the Diagnostics & Research subindustry, Vimta Labs's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimta Labs PE Ratio (TTM) vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Vimta Labs's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Vimta Labs's PE Ratio (TTM) for today is calculated as
Vimta Labs's Share Price of today is ₹616.30.
Vimta Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹17.66.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Vimta Labs (BOM:524394) has a PE Ratio (TTM) of 34.90 as of Aug. 16, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Vimta Labs and its competitors. This is 35% above median its historical median of 25.85. Over the past decade, Vimta Labs' PE Ratio (TTM) has ranged from 9.77 to 77.46. According to the industry distribution chart, Vimta Labs ranks #53 out of 96 companies in the Medical Diagnostics & Research industry, placing it in the top 55.2%.
Is Vimta Labs' PE Ratio (TTM) too high?
Vimta Labs' current PE Ratio (TTM) of 34.90 is 35% above median its 10-year median of 25.85. Over the past 10 years, this metric has ranged from a low of 9.77 to a high of 77.46. The Medical Diagnostics & Research industry median PE Ratio (TTM) is 32.57. Vimta Labs' value of 34.90 is 7.2% above this industry median. Based on the distribution chart, Vimta Labs ranks #53 out of 96 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Vimta Labs has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' PE Ratio (TTM) compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimta Labs ranks #53 out of 96 companies for PE Ratio (TTM). This places Vimta Labs in the lower half of its industry. The industry median PE Ratio (TTM) is 32.57. Vimta Labs' value of 34.90 is 7.2% above this benchmark. Historically, Vimta Labs' own PE Ratio (TTM) has ranged from 9.77 to 77.46 over the past decade. While the company's 10-year median is 25.85 vs. the industry median of 32.57, Vimta Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Diagnostics & Research company?
The median PE Ratio (TTM) among Medical Diagnostics & Research companies is 32.57, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimta Labs's current PE Ratio (TTM) of 34.90 is 7.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Vimta Labs and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio (TTM) is 32.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current PE Ratio (TTM) is 34.90, which is 35% above median its own 10-year median of 25.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹508.85, compared to a current price of ₹616.30 — trading 21.1% above its estimated fair value. The current PE Ratio (TTM) is 34.90, which is 35% above median its 10-year median of 25.85 and 7.2% above the Medical Diagnostics & Research industry median of 32.57. Vimta Labs' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current PE Ratio (TTM) is 34.90 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹616.30 is trading 21.1% above its estimated GF Value™ of ₹508.85.
GuruFocus considers Vimta Labs to be Modestly Overvalued.
Key valuation signals for BOM:524394:
PE Ratio (TTM): 34.90 (35% above median its 10-year median of 25.85)
GF Value™: ₹508.85 vs. price of ₹616.30 (21.1% above fair value)
Industry Position: 7.2% above the Medical Diagnostics & Research median (#53 of 96)
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
84GF Score
Get the complete analysis for BOM:524394
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
